Qiagen is a consumable molecular diagnostics and life-science tools platform and offers QuantiFERON, QIAstat-Dx, QIAcuity ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and ...

QuantiFERON: Accelerating workflow automation and AI-related investments QIAGEN is developing a fifth generation of its QuantiFERON test, with updates planned during 2026 as part of its commitment to ...

Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028 QIAGEN N.V. (NYSE: ...

Detecting latent tuberculosis infection (LTBI) is important, especially in high-risk populations including healthcare workers (HCWs). QuantiFERON-TB Gold Plus (QFT-Plus) is a new version of the ...

QuantiFERON grew 11% CER supported by solid gains in the Americas but also in EMEA as we maintain momentum in driving conversion of latent TB testing for the traditional skin test. Let us remember ...

The authors have declared no conflicts of interest. Background: Latent tuberculosis testing prior to immunosuppression is recommended by national and international guidelines. However, no structured ...

Objective To determine the cost-effectiveness of the QuantiFERON (QFT) test versus the tuberculin skin test (TST) in diagnosing latent tuberculosis infection (LTBI) in immunocompetent children under ...

Rates of sustained QuantiFERON-TB (QFT) test conversion did not differ significantly between Bacille Calmette-Guérin (BCG) revaccination and placebo. Alexander C. Schmidt, M.D., from the Gates Medical ...